The orphan drug maker has found a home for some of its operations in the low-tax country The tax advantages of doing business in Ireland have been plumbed by a number of drugmakers, some of whom have moved their homes there to cut taxes, and so costs. Alexion ($ALXN), maker of orphan drug Soliris, is bagging some of that benefit by expanding operations there. The Cheshire, CT-based company last year opened offices and labs in Dublin to expand its supply chain operations in Europe.

Now the drugmaker is buying a vial-filling facility there and moving some intellectual property rights for Soliris and other compounds to Ireland. The results of all of this, CFO Vikas Sinha said during its recent earnings call, will be a tax rate that will run 10% to 11% on a non-GAAP basis before rising in 2016 to 16% to 18%. As for the new facilities in that country, Alexion CEO Leonard Bell disclosed its deal to buy a vial-filling facility during the earnings call but didn't say from whom, for how much or where it was. According to a transcript of the call from Seeking Alpha, Bell said only that it "will become Alexion's first company-owned vialing facility for Soliris and our other clinical and commercial products."